Treatment and outcome of Hodgkin lymphoma (HL) are the true success story of modern medicine. The data from the developing countries on long-term outcome of patients with HL is sparse.
Aims: Primary objective is to assess the progression-free survival (PFS). Secondary objective are overall survival (OS) and toxicities.
Settings and design: This is a retrospective analysis from the case records from a single institution.
Materials and methods: Institutional Ethical Committee approval was obtained. Between January 1991 and December 2010, 301 patients (age ≥18 years) underwent treatment at our institution.
Statistical analysis: Kaplan-Meyer curves were used to calculate the PFS and OS.
Results: The median age at presentation was 36 years, range from 19 to 75 years. The male to female ratio was 2.9:1. Seventy-five percent of patients had B symptoms. Majority presented in advanced stage (Stage III and IV) disease (64.7%). Mixed cellularity (74.4%) was the most common histology, followed by nodular sclerosis (13.9%). The most common chemotherapy regimen used was ABVD (61%).
Conclusions: Median follow-up of the cohort was 18.5 months (range 2-225). PFS and OS rate at 5 years is 66.3% and 79.7% respectively.
Keywords: Chemotherapy and toxicities; Hodgkin lymphoma; survival.